Back to Archived News
Skinvisible Granted Comprehensive Patent for Invisicare® in India
Tuesday, August 21, 2007
Las Vegas, NV -- Skinvisible, Inc. (OTCBB: SKVI)(Website: http://www.skinvisible.com/), the developers of Invisicare, a proprietary polymer delivery system for topically applied dermatology products, is pleased to announce that it has been granted a comprehensive patent in India. The patent granted protects Invisicare in the areas of 'Topical Composition', 'Topical Composition Precursor', and 'Methods for Manufacturing and Using'.
These key patent components now allow for the protected manufacturing, marketing and distribution of Skinvisible's Invisicare technology and its formulated products in India. The key advantage of products formulated with Invisicare is its unique ability to hold active ingredients on the skin for extended periods of time while resisting wash-off, rub-off and perspiration. It has the ability to enhance topical skincare products, give an extended life to products coming off patent and be part of new formulations for over-the-counter and prescription dermatology products.
"With a population of over 1.1 billion people, India will be a key market for Skinvisible," said Mr. Terry Howlett, President and CEO of Skinvisible. "This patent approval informs our potential licensees that we are committed to protect our Intellectual Property as we work together to license our proprietary dermatology products in India and elsewhere. Skinvisible has filed for patent protection worldwide for Invisicare in order to meet the demands of our domestic and international pharmaceutical & cosmeceutical marketing partners."
This is the first patent approved in India for Skinvisible. The Company is also seeking patent protection for its dermatology products formulated with Invisicare for this country. Along with its domestic patents pending in the U.S. and Canada, additional international patents are pending for both Invisicare and products formulated with Skinvisible's delivery system technology.
Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare®. Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See: http://www.invisicare.com/
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare® to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See: http://www.skinvisible.com/
This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007).
Back to Archived News